Leerink Partnrs Upgrades Metsera (NASDAQ:MTSR) to "Strong-Buy"

Key Points

• Metsera (MTSR) received a "strong-buy" rating upgrade from Leerink Partners, highlighting positive analyst sentiment regarding the stock.
• Various analysts have set price targets for Metsera, with Guggenheim raising their target from $56 to $62 and Bank of America increasing theirs from $45 to $50.
• Metsera's shares traded up 4.6% recently, with a current trading price of $36.72, and a notable high of $47.40 in the past 52 weeks.

Metsera (NASDAQ:MTSR - Get Free Report) was upgraded by investment analysts at Leerink Partnrs to a "strong-buy" rating in a research note issued on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Metsera's Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($2.10) EPS, FY2026 earnings at ($3.32) EPS, FY2027 earnings at ($3.77) EPS, FY2028 earnings at ($3.80) EPS and FY2029 earnings at ($4.92) EPS.

MTSR has been the subject of several other research reports. Wall Street Zen cut shares of Metsera from a "hold" rating to a "sell" rating in a research report on Sunday, September 7th. Guggenheim increased their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Bank of America increased their target price on shares of Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Leerink Partners initiated coverage on shares of Metsera in a report on Tuesday. They issued an "outperform" rating and a $77.00 target price for the company. Finally, Wells Fargo & Company initiated coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $63.50.

Metsera Trading Down 4.2%

MTSR traded down $1.58 on Tuesday, hitting $35.67. 1,611,155 shares of the stock were exchanged, compared to its average volume of 1,335,429. Metsera has a 12 month low of $12.30 and a 12 month high of $47.40. The business has a 50-day moving average of $35.49 and a two-hundred day moving average of $28.87.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. raised its holdings in Metsera by 45.5% in the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock valued at $27,000 after buying an additional 296 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company's stock valued at $46,000 after buying an additional 800 shares during the last quarter. Strs Ohio bought a new position in Metsera in the 1st quarter valued at approximately $76,000. Virtus Investment Advisers LLC bought a new position in Metsera in the 2nd quarter valued at approximately $77,000. Finally, KLP Kapitalforvaltning AS bought a new position in Metsera in the 2nd quarter valued at approximately $122,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.